# PRV-3279-2a Trial in Systemic Lupus

> **NCT05087628** · PHASE2 · TERMINATED · sponsor: **Provention Bio, a Sanofi Company** · enrollment: 28 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** PRV-3279
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05087628
- **Lead sponsor:** Provention Bio, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-20
- **Primary completion:** 2024-05-14
- **Final completion:** 2024-06-24
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Termination for Strategic Reasons
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087628, "PRV-3279-2a Trial in Systemic Lupus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05087628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*